This month, we had the honor of welcoming Lehendakari Imanol Pradales and key members of his government team to our facilities; Mikel Jauregi, Minister of Industry, Energy Transition and Sustainability; Juan Ignacio Pérez Iglesias, Minister of Science, University, and Innovation; and Jaione Ganzarain, Deputy Minister of Technology, Innovation, and Digital Transformation.
During their visit, we had the opportunity to share Viralgen’s mission of bringing advanced treatments to those who need them most, to showcase the science that takes place in our laboratories and give insights on AAVs (Adeno-Associated Virus vectors) manufacturing process, critical to gene therapies.
We are deeply grateful to have hosted these important visitors/ stakeholders and appreciate the continuous support critical for developing innovative therapies in the Basque country. This visit strengthens our commitment to health and innovation, as we work together to advance progress in the field of gene therapies.
News
September 26, 2024
Visit of Lehendakari Imanol Pradales and his team to Viralgen facilities: A step forward in advancing gene therapies
Explore more
Insights
Advanced Therapies Conference Recap: Key Takeaways from Key CGT Fall Conferences
Our scientific and business teams at Viralgen have been crisscrossing the globe to get insights on our peers’ latest advances in cell and gene therapy – and to share our own. Here’s a quick rundown of what we heard during three key conferences in...
READ MORE
November 05, 2025
Resources
Webinar: What Comes Next? Industry Takeaways from FDA’s Cell and Gene Therapy Listening Session
The US Food and Drug Administration’s Office of Therapeutic Products (OTP) convened a public listening session on September 18, 2025, asking the cell and gene therapy (CGT) community how prior knowledge can be leveraged to accelerate the development...
READ MORE
October 17, 2025
Resources
Webinar: Making a meaningful impact in AAV
In October, Andy Holt, Chief Commercial Officer at Viralgen, provided attendees of Meeting on the Mesa 2025 with an update on three of the company’s latest initiatives to help innovators advance their gene therapies more efficiently: Plasmid...
READ MORE
October 17, 2025